期刊文献+

宫颈癌中表皮生长因子受体基因状态的研究进展 被引量:6

原文传递
导出
摘要 宫颈癌是严重威胁女性健康的第二大恶性肿瘤,在发展中国家其发病率和死亡率约占女性所有恶性肿瘤的15%,严重影响了妇女及其家庭的生活质量。近年来,宫颈癌患病的“年轻化”趋势十分明显,20~30岁患者的发病率呈上升趋势,因此,宫颈癌的病因学研究成为热点并取得了突破性的进展。宫颈癌的发生是多因素、多基因参与且呈多阶段发展的生物学过程,人乳头瘤病毒的感染被公认为宫颈癌的主要发病因素,但并不是唯一的因素。
出处 《中国妇幼保健》 CAS 2015年第15期2465-2467,共3页 Maternal and Child Health Care of China
基金 江西省科技厅科学基金资助项目〔20133BBG70069〕
  • 相关文献

参考文献23

  • 1郭历琛,赵先兰,史惠荣,张梅,翟军.LRIG3基因在宫颈癌组织中的表达及其病理学意义[J].中国妇幼保健,2013,28(25):4226-4229. 被引量:3
  • 2Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer [ J ]. Cancers, 2011, 3 (2): 1513-1526.
  • 3Moerkens M, Zhang Y, Wester L, et al. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor c signalling and results in tamoxifen insensitive proliferation [ J]. BMC Cancer, 2014, 14 (1): 283.
  • 4Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression [J ]. Genome Res, 2012, 22 (7): 1197-1211.
  • 5Samudio - Ruiz SL, Hudson LG. Increased DNA methyhransferase activity and DNA methylation following epidermal growth factor stimulation in ovarian cancer cells [J]. Epigeneties, 2012, 7 (3):216-224.
  • 6周少贞,李相辉,张玉祥.EGFR基因启动子区甲基化状态分析[J].中国生物化学与分子生物学报,2010,26(6):568-574. 被引量:6
  • 7Li Q, Tang Y, Cheng X, et al. EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix [ J]. Int J Clin Exp Pathol, 2014, 7 (2):733-741.
  • 8周素英,冯国飞,陈国荣,潘丹,张品南,杨小敏,夏作利.子宫颈鳞癌组织中表皮生长因子受体的表达及其基因状态分析[J].中华妇产科杂志,2013,48(11):843-846. 被引量:5
  • 9Iida K, Nakayama K, Rahman MT, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target [J]. Br J Cancer, 2011, 105( 3 ) : 420-427.
  • 10Schrevel M, Gorter A, Kolkman-Uljee SM, et al. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer [J]. Mod Pathol, 2011, 24 (5) : 720-728.

二级参考文献62

  • 1Zuo-Xiang Li,Xu Ma,Zhao-Hui Wang.A differentially methylated region of the DAZ1 gene in spermatic and somatic cells[J].Asian Journal of Andrology,2006,8(1):61-67. 被引量:3
  • 2刘俊丽,陈元,蔡煜,张敏.选择性EGFR酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用[J].肿瘤防治研究,2007,34(7):480-482. 被引量:8
  • 3曾瑄,王鹏,武莎斐,高洁,梁智勇,刘彤华.结直肠癌EGFR和HER2蛋白表达及其基因拷贝数分析[J].中华病理学杂志,2007,36(7):447-452. 被引量:8
  • 4Ratushny V, Astsaturov l, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer [J]. Cell Signal, 2009, 21(8): 1255-1268.
  • 5Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small-cell lung cancer [Jl. MedOncol, 2010, 27(1): 91-97.
  • 6Matkovic B, Juretic A, Separovic V, Novosel I, Separovic R, Gamulin M, et al. hnmunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer [J].Tumor, 2008,94(6) : 838-844.
  • 7Molaei M, Pejhan S, Nayer BN, Moradi A, Ghiasi S, Zali MR. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: Correlation with survival and clinicopathological findings [J]. Eur J Gastroenterol Hepatol, 2009, 21 (3) : 289- 293.
  • 8Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [ J ]. J Clin Oncol, 2003,21 (14) : 2787-2799.
  • 9Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350(21 ) : 2129-2139.
  • 10Paez JG, Janne PA, Lee JC, Lee JC, Tracy S, Greulich H, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy [ J ]. Science, 2004, 304 ( 5676 ) : 1497- 1500.

共引文献22

同被引文献41

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部